Health
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial – The Lancet
Dabrafenib plus trametinib combination treatment showed promising activity in patients
with BRAFV600E-mutated biliary tract cancer, with a manageable safety profile. Routine
testing for BRAFV600E mutations should be considered in patients with biliary tract
c…
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
-
General19 hours agoYoung boy flown to Brisbane hospital after K’gari dingo attack
-
General17 hours agoBritish and US planes fly 12-hour mission to patrol Russian border
-
Noosa News20 hours agoWarm weather could make way for rain with ‘damaging winds, large hail’
-
General5 hours agoByford rail extension opening marks final stage of Perth Metronet